Close Menu

NEW YORK (GenomeWeb) – DermTech announced on Monday that it has secured payor coverage for its pigmented lesion assay (PLA) from CareFirst Blue Cross/Blue Shield and its affiliate CareFirst BlueChoice.

The non-invasive assay is designed to analyze the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions. DermTech said that CareFirst will now cover the test for its 3.4 million members, effective for claims for services performed on or after June 1.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.